Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer’s disease (AD) is the leading cause of dementia. Currently, there are no effective disease-modifying treatments for AD. Mendelian randomisation (MR) has been widely used to repurpose licensed drugs and discover novel therapeutic targets. Thus, we aimed to identify novel therapeutic targets for AD and analyse their pathophysiological mechanisms and potential side effects. Methods: A two-sample MR integrating the identified druggable genes was performed to estimate the causal effects of blood and brain druggable expression quantitative trait loci (eQTLs) on AD. A repeat study was conducted using different blood and brain eQTL data sources to validate the identified genes. Using AD markers with available genome-wide association studies data, we evaluated the causal relationship between established AD markers to explore possible mechanisms. Finally, the potential side effects of the druggable genes for AD treatment were assessed using a phenome-wide MR. Results: Overall, 5883 unique druggable genes were aggregated; 33 unique potential druggable genes for AD were identified in at least one dataset (brain or blood), and 5 were validated in a different dataset. Among them, three prior druggable genes (epoxide hydrolase 2 (EPHX2),SERPINB1 and SIGLEC11) reached significant levels in both blood and brain tissues. EPHX2 may mediate the pathogenesis of AD by affecting the entire hippocampal volume. Further phenome-wide MR analysis revealed no potential side effects of treatments targeting EPHX2,SERPINB1 or SIGLEC11. Conclusions: This study provides genetic evidence supporting the potential therapeutic benefits of targeting the three druggable genes for AD treatment, which will be useful for prioritising AD drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MR-Base platform supports systematic causal inference across the human phenome
Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., et al. (2018) · eLife · doi:10.7554/elife.34408 · Cited by 7,959
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., & Plagnol, V. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004383 · Cited by 4,261
Võsa, U., Claringbould, A., Westra, H.-J., Bonder, M. J., Deelen, P., Zeng, B., Kirsten, H., Saha, A., Kreuzhuber, R., Yazar, S., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00913-z · Cited by 2,607
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498 · cited 4×
“In addition, our initial findings were based on AD GWAS, including clinical and proxy cases.”
MethodInfluentialSelf-citationNichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
Self-citationMendelian Randomization as an Approach to Assess Causality Using Observational Data
Sekula, P., Del Greco M, F., Pattaro, C., & Köttgen, A. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010098 · Cited by 2,351 · cited 1×
“12 MR analysis has been widely used to repurpose licensed drugs 13 and discover novel therapeutic targets 14 15 by integrating summary data from disease GWASs and expression quantitative trait locus (eQTL) studies.”
MethodDetecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome
Greco M, F. D., Minelli, C., Sheehan, N. A., & Thompson, J. R. (2015) · Statistics in Medicine · doi:10.1002/sim.6522 · Cited by 1,700
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666 · cited 1×
“9 10 In other words, ‘druggable’ genes encoding proteins or gene expression can provide powerful clues to inform drug targets.”
Background
Cited by
Artificial intelligence for drug discovery and development in Alzheimer's disease
Qiu, Y., & Cheng, F. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102776 · Cited by 83
Zhan, H., Cammann, D., Cummings, J. L., Dong, X., & Chen, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06317-5 · Cited by 17
Li, J., Qiu, K., Rao, Y., Cheng, D., Song, Y., Shao, X., Jiang, C., Shu, T., Xu, W., Zhao, Y., et al. (2026) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-026-10663-5
Metadata
- Authors
- Su, W.-M., Gu, X.-J., Dou, M., Duan, Q.-Q., Jiang, Z., Yin, K.-F., Cai, W.-C., Cao, B., Wang, Y., & Chen, Y.-P.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2023-06-22
- Volume
- 94
- Issue
- 11
- Pages
- 954-961
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W4381612968
- Cited by
- 161
- References
- 23
- FWCI
- 23.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease. https://app.cochat.ai/papers/10.1136/jnnp-2023-331142
- The paper
- Su, W.-M., Gu, X.-J., Dou, M., Duan, Q.-Q., Jiang, Z., Yin, K.-F., Cai, W.-C., Cao, B., Wang, Y., & Chen, Y.-P. (2023). Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2023-331142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.